Correction: Single-cell and spatial profiling reveal an IL-10–associated iCAF–M2 macrophage communication axis in high-grade serous ovarian cancer ascites Authors: Ren Li, Jinquan Xia, Chang Zou, Yixia Xie, Yuan Shen Published: 2026 There was a mistake in Figure 6 as published. “Panel H” was not fully uploaded during the proof stage. The corrected Figure 6 appears below. IL10 blockade with MK-1966 suppresses tumor growth and decreases IL10 pathway activity in humanized PDX models. (A) Schematic of humanized ovarian cancer PDX model generation and MK-1966 treatment timeline. (B) Representative tumor images demonstrating visibly smaller tumors in MK-1966–treated mice. (C) Tumor growth curves showing significantly reduced tumor volume following MK-1966 treatment (n = 5, p < 0.001). (D) Final tumor weight demonstrating significantly lower tumor mass in treated mice (n = 5, p < 0.001). (E) Representative IHC staining showing decreased CD206, IL-10, and IL-10RA expression in MK-1966 tumors versus controls. (F) Quantitative IHC scoring confirming significant reductions in CD206 (p < 0.01) and IL-10 and IL-10RA (p < 0.05) following treatment. N = 3. (G) Representative multiplex immunofluorescence staining of DAPI (blue), EpCAM (green), and Ki67 (red) demonstrating co-localization of Ki67-positive proliferating cells within EpCAM-positive tumor cells. MK-1966 treatment markedly reduced EpCAM+/Ki67+ double-positive tumor cells compared with controls. (H) Quantitative analysis of EpCAM+/Ki67+ relative fluorescence intensity demonstrating significantly decreased tumor-cell proliferative activity following MK-1966 treatment (**p< 0.01). *represent p-value < 0.05; *** represent p-value < 0.001. The original version of this article has been updated. There was a mistake in the caption of Figure 6 as published. We conducted multiplex immunofluorescence staining on tumor tissues from a mouse PDX model. By detecting Ki67 and EpCAM in tumor tissues, we aimed to elucidate the impact of blocking the IL-10 signaling axis on tumor tissues. Therefore, the original description of immunohistochemical scoring for Ki67 was no longer necessary. The corrected caption of Figure 6 appears below. “(E) Representative IHC staining showing decreased CD206, IL-10, and IL-10RA expression in MK-1966 tumors versus controls. (F) Quantitative IHC scoring confirming significant reductions in CD206 (p < 0.01) and IL-10 and IL-10RA (p < 0.05) following treatment. N = 3.” The original version of this article has been updated. “We conducted multiplex immunofluorescence staining on tumor tissues from a mouse PDX model. By detecting Ki67 and EpCAM in tumor tissues, we aimed to elucidate the impact of blocking the IL-10 signaling axis on tumor tissues. Therefore, the original description of immunohistochemical scoring for Ki67 was no longer necessary.” A correction has been made to the section Results, IL10 blockade with MK-1966 suppresses tumor growth in humanized PDX models, Paragraph 1: “The treatment schema is shown in Figure 6A, illustrating the generation of humanized mice using human PBMCs followed by establishment of ovarian cancer PDX tumors and subsequent MK-1966 administration. In immune-humanized ovarian cancer PDX mice,treatment with the IL10 monoclonal antibody MK-1966 resulted invisibly smaller tumors compared with controls (Figure 6B). Longitudinal tumor monitoring demonstrated a progressive reduction in tumor volume in the MK-1966 group, whereas tumors in control mice continued to enlarge, with a significant difference observed by day 21 (p< 0.001, Figure 6C). Final tumor weight measurements confirmed this effect, showing substantially lower tumor mass in MK-1966–treated mice compared with controls (p < 0.001, Figure 6D).Immunohistochemical analysis revealed marked reductions in CD206, IL10, and IL10RA staining in tumors from MK-1966–treated mice relative to controls (Figure 6E). Quantitative scoring demonstrated significantly decreased expression of CD206 (p< 0.01), and reduced IL10 and IL10RA expression (p< 0.05) in treated tumors (Figure 6F). These results showed that MK-1966 treatment is associated with reduced tumor burden and decreased expression of IL10 pathway components and M2-associated markers in humanized ovarian cancer PDX tumors. To further determine whether MK-1966 reduced proliferation specifically in tumor cells, multiplex immunofluorescence costaining was performed using the epithelial tumor marker EpCAM together with Ki67. In control tumors, abundant Ki67-positive nuclei colocalized with EpCAM-positive tumor cells, indicating active proliferation within the malignant epithelial compartment (Figure 6G). In contra st, MK-1966 treatment markedly reduced the proportion of EpCAM+/Ki67+ double-positive cells. Quantitative analysis. demonstrated a significant decrease in the relative intensity of proliferating EpCAM-positive tumor cells in the MK-1966 group compared with controls (p < 0.01, Figure 6H). These findings further support that IL10 blockade suppresses ovarian tumor progression by reducing tumor-cell proliferative activity and attenuating immunosuppressive IL10-associated signaling within the tumor microenvironment.” The original version of this article has been updated.